~~<i id='C6AD5638E3'><strike id='C6AD5638E3'><tt id='C6AD5638E3'><pre id='C6AD5638E3'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

focus

author：entertainment 2025-09-05 06:47:13 - browse：29

Calling Bullshit course University of Washington — Screenshot via callingbullshit.org

Tired of alternative facts, fake news, and breathless hyperbole, two professors at the University of Washington are trying to strike a blow for science.

Their weapon? A new course: “Calling Bullshit In the Age of Big Data.”

The class website and colorful syllabus went online last month and almost instantly went viral.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： NYU radiologists take on the challenge of expensive MRI machines

explore

knowledge

entertainment

Wikipedia

hotspot

Whopolicesalgorithms?HowwouldyounamethefirstapprovedCRISPRmedicine?Andwhatpairswellwithabiotechdownt

WSS

ASCO: AstraZeneca says CAR

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

Ransomware attacks on hospitals: Study outlines patient impact

The Pandemic Treaty must support building strong health systems

Poor hospice wound care hurts patients and families

With trial win, GSK could get blood cancer drug back on market

leisure time

focus

explore

Heart attack and stroke risk calculators need revising

ASCO: AstraZeneca says CAR

Activists slam private health insurers over coverage restrictions

Morphosys mixed study results for blood cancer drug

Bright Health sells Medicare Advantage business to Molina

See how much Covid

Cancer drug shortages should be causing more outrage

NIH documents show early flaws of $1.6 billion long Covid program

Virginia high school admissions case could be legal follow

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

knowledge

CRISPR pioneers react to Casgevy, first gene

ASCO: Palliative care found as helpful given virtually as in person

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Woman returns to dialysis after doctors remove transplanted pig kidney

Ultragenyx gene therapy for rare liver ailment succeeds in late

knowledge

entertainment

Wikipedia

hotspot